GSK (LON:GSK) Receives “Buy” Rating from Citigroup

Citigroup reissued their buy rating on shares of GSK (LON:GSK) in a research note released on Tuesday morning, Marketbeat.com reports. The brokerage currently has a GBX 1,900 price objective on the stock.

A number of other equities research analysts have also recently commented on GSK. UBS Group restated a “neutral” rating and issued a GBX 1,940 price target on shares of GSK in a report on Friday, January 23rd. Berenberg Bank raised their target price on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on GSK from GBX 1,600 to GBX 1,675 and gave the stock a “hold” rating in a research report on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, GSK has an average rating of “Hold” and an average target price of GBX 1,839.29.

GSK Stock Down 2.3%

Shares of LON:GSK opened at GBX 1,819.46 on Tuesday. GSK has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 1,909.73. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The business’s 50-day moving average is GBX 1,819.46 and its 200-day moving average is GBX 1,638.89. The company has a market capitalization of £73.40 billion, a price-to-earnings ratio of 13.68, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Equities research analysts predict that GSK will post 175.980975 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Wendy Becker acquired 441 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were acquired at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds bought 1,650 shares of the firm’s stock in a transaction on Monday, December 22nd. The stock was purchased at an average cost of GBX 1,810 per share, with a total value of £29,865. Insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.